| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
In recent years, various treatment study for the anti-resorptive agents-related osteonecrosis of the jaw (ARONJ) is carried out. We examined a surgical management for ARONJ using Platelet-rich fibrin, but it was not approved by the Act on Securing Safety of Regenerative Medicine.
The occurrence of ARONJ in our department was higher than previous reports. We changed the policy not to take a drug holiday before teeth extraction and there is no evidence that it is effective to prevent the onset of ARONJ by taking a drug holiday. The cure rate of ARONJ caused by osteoporosis was higher than ARONJ due to a malignant tumor and the surgical management for ARONJ was better cured than conservative therapy. In the comparison by FDG-PET, ARONJ showed a high accumulation compared to other osteomyelitis of jaw and increased activity of inflammation was shown.
|
